相关实验视频
Updated: May 16, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
732
控制的抗溶剂沉,以提高蒂卡格雷洛的溶解率和抗血小板活性
Asmaa M Eldeeb1, Dalia H Abdelkader1,2, Gamal M El Maghraby1
1Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Pharmaceutical development and technology
|April 9, 2025
概括
控制的抗溶剂沉增强了ticagrelor的作用.
科学领域:
- 制药科学 制药科学
- 材料科学 材料科学 材料科学
背景情况:
- 提卡格勒勒 (TC) 是一种抗血小板药物.
- 改善TC的溶解速率和抗血小板活性在临床上是重要的.
研究的目的:
- 为了增加蒂卡格勒罗的溶解率和抗血小板活性,使用受控的抗溶剂沉.
- 为了评估波洛克萨默188和凝44/14对TC沉的影响.
主要方法:
- 使用乙醇-水系统对TC进行受控的抗溶剂沉.
- 加入了波洛克萨默188或凝44/14和气200.
- 通过FTIR,DSC,PXRD和体外溶解研究进行表征.
- 通过大鼠的尾部出血时间评估抗血小板活性.
主要成果:
- 观察到TC的部分无形化,DSC和PXRD证实了这一点.
- 在溶解效率和速率上显著提高.
- 配方F6 (TC,Poloxamer,Aerosil) 和F9 (TC,Gelucire,Aerosil) 显示出最好的性能. 这两种配方的性能都比较好.
- 在接受F6和F9治疗的老鼠中,尾部出血时间延长,表明抗血小板活性增加.
结论:
- 控制的抗溶剂沉是一种有效的方法,可以提高TC的溶解率和生物可用性.
- 开发的配方显示出改善的药理活性.
- 这种技术提供了一种简单的方法来提高蒂卡格雷勒的治疗效果.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
420
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
420
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Colloidal precipitates
457
The high insolubility of some precipitates can result in an unfavorable relative supersaturation. This can lead to colloidal particles with a large surface-to-mass ratio, where adsorption is promoted. For instance, in the precipitation of silver chloride, silver ions are adsorbed on the surface of the colloidal particles, forming a primary layer. This layer attracts ions of opposite charge (such as nitrate ions), forming a diffuse secondary layer of adsorbed ions. This electric double layer...
457
Anticoagulant Drugs: Low-Molecular-Weight Heparins
570
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
570
Factors Affecting Dissolution: Particle Size and Effective Surface Area
647
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
647

